Aptar Pharma said today that the European Medicines Agency approved its electronic nasal lockout device, e-Lockout. The device is the 1st and only fully-integrated electronic nasal drug delivery device to be approved by a European regulatory authority, according to the company.
The e-Lockout device is a part of a multi-year development deal with Takeda Pharmaceuticals International (TYO:4502). Aptar agreed to supply its e-Lockout device for use with Takeda’s multi-dose nasal spray version of a fast-acting opioid, Instanyl.
Takeda plans to launch a uni-dose and multi-dose version of its nasal spray with Aptar’s electronic lockout system in Europe.